cAMP antagonists


Koordiniert durch:Wenche M. Olsen, Oslo, NOR
Förderungszeitraum:von Sept 2003 bis Aug 2005

New cAMP antagonists

Drugs for immunomodulating therapy in HIV and other immunodeficiencies could possibly assist the immune system in driving out the HIV virus, and is expected to lower the incidence of opportunistic infections in several immunodeficiencies.
The technology in the project is based on new knowledge showing that activation of a signal pathway involving the signal substance cAMP and protein kinase A type I, PKAI, inside white blood cells, T lymphocytes, inhibits the function of the immune system. During HIV infection, the activity of this signal pathway is greatly increased due to elevated levels of cAMP and the function of the patient’s white blood cells is strongly reduced. Development of immunostimulatory drugs that interfere with cAMP action by targeting and disrupting the cAMP/PKA type I signalling pathway will improve the immune function of T lymphocytes. In vivo experiments and ex vivo clinical testing of compounds are on-going.
The project will aim for treatment protocols that can help eradicate HIV and lower the total cost of treatment or simplify administration of the total treatment.